Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
Keywords
Abstract
Description
Title: Study of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis Study design: A randomized, double blind, placebo-controlled trial with 2 parallel arms Sample size: 247 Inclusion criteria: Age 15 years or older; HIV antibody positive; clinical diagnosis of TBM.
Exclusion criteria: positive CSF Gram or India ink stain, known or suspected pregnancy; antituberculous treatment 8 to 30 days immediately prior to recruitment; previous antiretroviral therapy; laboratory contraindications to antiretroviral or antituberculous therapy; lack of consent.
Consent: Written informed consent will be sought for all patients. Verbal consent will be considered acceptable when written consent is impossible. In unconscious patients, the consent of 2 independent physicians will be considered acceptable.
Randomization: Patients will be stratified according to TBM disease severity at presentation (modified MRC grade I to III). Within each stratum, patients will be randomized to 1 of the 2 treatment arms: immediate or deferred (2 months) ART.
Antituberculous treatment: Initial therapy will be with isonazid, rifampicin, pyrazinamide and ethambutol for 3 months. After 3 months, patients will continue on rifampicin and isoniazid for a further 6 months.
Corticosteroid treatment: Dexamethasone 0.3 - 0.4mg/kg will be administered and tapered over 6 - 8 weeks, according to TBM grade.
Antiretrovira l treatment: Antiretrovirals (zidovudine, lamivudine and efavirenz)or identical placebo tablets will be commenced at study entry and continued for 2 months. Thereafter, all patients will received antiretrovirals.
Clinical monitoring: Patients will be assessed weekly as an inpatient for 3 months. Hospital outpatient review will occur monthly until 9 months. A final follow-up visit will take place at 12 months.
Laboratory monitoring: Routine laboratory tests will be monitored weekly as an inpatient and monthly as an outpatient. Blood samples for CD4 T-lymphocyte count and plasma HIV-1 RNA level will be monitored 3-monthly. CSF samples will be taken at 0, 1, 2, 3, 6 and 9 months.
Radiology: Patients will have a chest radiograph performed on admission. A CT or MRI brain scan may also be performed if clinically indicated.
Adverse events: All grade 3 and 4 adverse events will be reported immediately to the Data and Safety Monitoring Committee.
Outcome measures: The primary endpoint will be mortality at 9 months. The secondary endpoints will be: mortality at 12 months; fever clearance time; coma clearance time; neurological relapse; progression to new or recurrent AIDS defining illness; any grade 3 or 4 adverse event; CD4 count response; plasma HIV-1 RNA response; neurological disability.
Data analysis: Analysis will be based on intention to treat.
Dates
Last Verified: | 05/31/2008 |
First Submitted: | 01/24/2007 |
Estimated Enrollment Submitted: | 02/08/2007 |
First Posted: | 02/11/2007 |
Last Update Submitted: | 08/05/2008 |
Last Update Posted: | 08/06/2008 |
Actual Study Start Date: | 08/31/2005 |
Estimated Primary Completion Date: | 11/30/2008 |
Estimated Study Completion Date: | 11/30/2008 |
Condition or disease
Intervention/treatment
Drug: Combivir and efavirenz
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Experimental: 1 Combivir, efavirenz for 12 months | |
Placebo Comparator: 2 Placebo for 2 months followed by Combivir and efavirenz for 10 months |
Eligibility Criteria
Ages Eligible for Study | 15 Years To 15 Years |
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - age 15 years or older - HIV antibody positive - clinical diagnosis of TB meningitis Exclusion Criteria: - positive CSF Gram or India ink stain - known or suspected pregnancy - antituberculous treatment 8 - 30 days immediately prior to recruitment - previous antiretroviral therapy - laboratory contraindications to antiretroviral or antituberculous therapy - lack of consent. |
Outcome
Primary Outcome Measures
1. Mortality [9 months]
Secondary Outcome Measures
1. Mortality [12 months]
2. Fever clearance time [undefined]
3. Coma clearance time [undefined]
4. CD4 count [12 months]
5. plasma HIV RNA [12 months]
6. Grade 3 or 4 adverse event [Any]
7. Neurological disability [12 months]